Literature DB >> 17551324

Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents.

Styliani Vlachou1, George G Nomikos, David N Stephens, George Panagis.   

Abstract

Data on the ability of Delta 9-tetrahydrocannabinol (THC) to modify reward processes in experimental animals are inconsistent. This study examined the effects of Delta 9-THC on brain reward function using the rate-frequency curve shift paradigm of intracranial self-stimulation (ICSS) and the conditioned place preference (CPP) paradigm. In ICSS tests, rats were implanted with electrodes into the medial forebrain bundle. After brain stimulation reward thresholds stabilized, rats received intraperitoneal injections of Delta 9-THC (0, 0.5, 1 and 2 mg/kg) or the CB1 receptor antagonist SR141716A (0, 0.02 mg/kg) and Delta 9-THC (0, 2 mg/kg). The two highest doses of Delta 9-THC significantly increased the threshold ICSS frequency. SR141716A reversed the action of Delta 9-THC (2 mg/kg), without affecting reward thresholds by itself. In the CPP test, mice received intraperitoneal injections of Delta 9-THC (0, 1 or 3 mg/kg). Delta 9-THC showed neither statistically significant preference nor aversion in either of the doses tested. These findings indicate that Delta 9-THC, in contrast to other drugs of abuse, does not facilitate ICSS or support CPP under the present experimental conditions, but rather has a dose-dependent inhibitory influence on ICSS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551324     DOI: 10.1097/FBP.0b013e3282186cf2

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  31 in total

1.  Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Authors:  Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-11-14       Impact factor: 4.030

Review 2.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 3.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

4.  Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats.

Authors:  Krista J Spiller; Guo-Hua Bi; Yi He; Ewa Galaj; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2019-04-03       Impact factor: 8.739

5.  Effect of footshock stress on place conditioning produced by Δ9-tetrahydrocannabinol and the fatty acid amide hydrolase (FAAH) inhibitor, URB597, in Sprague-Dawley rats.

Authors:  Marieka V DeVuono; Kiri L Wills; Danielle V MacPherson; Kelly M Hrelja; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-08-12       Impact factor: 4.530

Review 6.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

7.  Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Authors:  Timothy W Lefever; Julie A Marusich; Kateland R Antonazzo; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2014-01-09       Impact factor: 3.533

8.  Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.

Authors:  Julie A Marusich; Jenny L Wiley; Timothy W Lefever; Purvi R Patel; Brian F Thomas
Journal:  Neuropharmacology       Date:  2017-11-04       Impact factor: 5.250

Review 9.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 10.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.